肺癌分子靶向治疗EGFR-TKI患者证候及中医处方用药研究进展  

Research progress on Syndrome Types and Prescription Medication of Traditional Chinese Medicine of EGFR-TKI Patients Treated by Molecular Targeted Therapy of Lung Cancer

作　　者：张迪 陈浩然 王家政 陈亚飞 刘浩[1] ZHANG Di;CHEN Haoran;WANG Jiazheng;CHEN Yafei;LIU Hao(Guang'anmen Hospital,Chinese Academy of Chinese Medical Sciences,Beijing 100053,China;Beijing University of Chinese Medicine,Beijing 100029,China)

机构地区：[1]中国中医科学院广安门医院,北京100053 [2]北京中医药大学,北京100029

出　　处：《中华中医药学刊》2024年第4期171-174,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：国家自然科学基金面上项目(81573950)。

摘　　要：表皮生长因子受体酪氨酸激酶抑制剂(Epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)是肺癌治疗领域的里程碑,中医药与分子靶向治疗EGFR-TKI相结合是肺癌综合治疗的新模式。辨证论治是中医的特色,中医药的精准配合,可以贯穿于分子靶向治疗EGFR-TKI的全程。通过查阅、归纳及分析近年来不同专家学者对分子靶向治疗EGFR-TKI相关肺癌患者不同治疗阶段的中医证候及中医处方用药研究的文献,总结肺癌分子靶向治疗EGFR-TKI患者在不同治疗阶段的证候分布及中医处方用药特点,促使中医辨证论治更加精准,旨在进一步提高临床上中医药配合分子靶向治疗EGFR-TKI的效果。Epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)is a milestone in the field of lung cancer treatment,and the combination of traditional Chinese medicine and molecular targeted therapy EGFR-TKI is a new mode of comprehensive treatment of lung cancer.The treatment based on syndrome differentiation is the characteristic of traditional Chinese medicine.The precise cooperation of traditional Chinese medicine can run through the whole process of molecular targeted treatment of EGFR-TKI.Through consulting,summarizing and analyzing the literature of different experts and scholars in recent years on the research of TCM syndromes and TCM prescriptions for different treatment stages of molecular targeted treatment of EGFR-TKI related lung cancer patients,it summarized the distribution of syndromes and the characteristics of TCM prescriptions for different treatment stages of EGFR-TKI patients with molecular targeted treatment of lung cancer,so as to promote the accuracy of TCM syndrome differentiation and treatment,the aim is to further improve the clinical efficacy of traditional Chinese medicine combined with molecular targeted therapy of EGFR-TKI.

关 键 词：肺癌 分子靶向治疗 表皮生长因子受体酪氨酸激酶抑制剂 证候 中医处方用药 

分 类 号：R273.342[医药卫生—中西医结合]